Abstract
Background: Diabetes Mellitus (DM) accelerates progress of lung cancer. Hyperglycemia, a critical feature of DM, promotes lung cancer metastasis. Mogroside V is a triterpenoid glycoside from Siraitia grosvenorii. Interestingly, mogroside V not only plays an anti-diabetic role, but also has anti-tumor effects.
Objective: In this study, we investigated the metastatic efficiency of mogroside V in lung cancer cells cultured in hyperglycemia.
Methods: Two lung cancer cell lines-A549 and H1299 were cultured in normoglycemia (5.5mM glucose) and hyperglycemia (25mM glucose). Cellular proliferation was tested by MTT, invasion was examined by transwell assay, migration was measured by wound healing assay, cytoskeleton was stained by Phalloidin-TRITC and the expressions of EMT markers and Rho-GTPase family protein were detected by western blot.
Results: Hyperglycemia promoted the invasion and migration of A549 and H1299 cells compared with normoglycemia. Mogroside V inhibited the hyperglycemia-induced invasion and migration. Hyperglycemia promoted epithelial-mesenchymal transition (EMT), while mogroside V could reverse this process through up-regulating E-Cadherin expression and down-regulating N-Cadherin, Vimentin, Snail expressions. Furthermore, mogroside V fractured microfilaments and reduced Rho A, Rac1, Cdc42 and p-PAK1 expressions under hyperglycemic conditions.
Conclusion: These results suggest that mogroside V inhibits hyperglycemia-induced lung cancer cells migration and invasion through reversing EMT and damaging cytoskeleton.
Keywords: Mogroside V, hyperglycemia, metastasis, EMT, cytoskeleton, lung cancer.
Graphical Abstract
[http://dx.doi.org/10.3389/fonc.2018.00281] [PMID: 30101126]
[http://dx.doi.org/10.3892/mco.2017.1224] [PMID: 28588788]
[http://dx.doi.org/10.1186/s12957-018-1362-1] [PMID: 29558957]
[http://dx.doi.org/10.1016/j.ygyno.2018.02.003] [PMID: 29458977]
[http://dx.doi.org/10.1016/j.canlet.2018.01.031] [PMID: 29331421]
[http://dx.doi.org/10.1016/j.jhep.2016.12.016] [PMID: 28025059]
[http://dx.doi.org/10.1159/000373928] [PMID: 25661467]
[http://dx.doi.org/10.1016/j.canlet.2017.12.004] [PMID: 29222037]
[http://dx.doi.org/10.1530/ERC-18-0036] [PMID: 29941677]
[http://dx.doi.org/10.1038/s41598-018-30449-y] [PMID: 30093732]
[http://dx.doi.org/10.1007/s00216-012-6693-0] [PMID: 23341001]
[http://dx.doi.org/10.1002/mnfr.200500252] [PMID: 16835866]
[http://dx.doi.org/10.1073/pnas.1604828113] [PMID: 27821754]
[http://dx.doi.org/10.1016/S0304-3835(03)00285-4] [PMID: 12893428]
[http://dx.doi.org/10.1038/oncsis.2016.28] [PMID: 27065453]
[http://dx.doi.org/10.1038/s41586-018-0350-5] [PMID: 30022161]
[http://dx.doi.org/10.1038/jcbfm.2013.151] [PMID: 23963366]
[http://dx.doi.org/10.1159/000494237] [PMID: 30308493]
[http://dx.doi.org/10.3389/fphar.2018.00807] [PMID: 30116189]
[http://dx.doi.org/10.1016/j.biopha.2016.09.062] [PMID: 27668542]
[http://dx.doi.org/10.1039/C8FO01486H] [PMID: 30516208]
[http://dx.doi.org/10.3390/molecules23081894] [PMID: 30060618]
[http://dx.doi.org/10.1042/BSR20171014] [PMID: 29367413]
[http://dx.doi.org/10.1016/j.csbj.2018.10.006] [PMID: 30455857]
[http://dx.doi.org/10.1016/j.ceb.2016.06.002] [PMID: 27371787]
[http://dx.doi.org/10.1007/s10555-016-9648-7] [PMID: 27878502]
[http://dx.doi.org/10.1016/j.bbamcr.2018.10.003] [PMID: 30296500]
[http://dx.doi.org/10.1016/j.biocel.2012.11.003] [PMID: 23153508]